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Abstract: The stable insertion of a copy of their genome into the host cell genome is an 
essential step of the life cycle of retroviruses. The site of viral DNA integration, mediated 
by the viral-encoded integrase enzyme, has important consequences for both the virus and 
the host cell. The analysis of retroviral integration site distribution was facilitated by the 
availability of the human genome sequence, revealing the non-random feature of 
integration site selection and identifying different favored and disfavored genomic 
locations for individual retroviruses. This review will summarize the current knowledge 
about retroviral differences in their integration site preferences as well as the mechanisms 
involved in this process. 
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1. Introduction  
The principal feature of retroviruses is that upon entry and release of their viral RNA genome into 
the cytoplasm of the host cell, it is reverse transcribed by the viral reverse transcriptase into a linear 
double stranded cDNA copy (Figure 1A) (for reviews, see [1-4]). This viral DNA is not naked, but is 
associated with viral and cellular proteins in a nucleoprotein complex called the preintegration 
complex (PIC). Depending on the retrovirus, the PIC is subsequently translocated into the nucleus, 
either actively through nuclear pores, or upon nuclear membrane disruption occurring during mitosis. 
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There, it is, either integrated into the genome of the host cell, or remains unintegrated for a certain 
time, or is degraded (Figure 1) (for reviews, see [3,5]). 
The insertion of the viral DNA into the host cell genome is catalyzed by the virally encoded 
integrase (IN) enzyme (for reviews, see [6-9]). Retroviral INs typically range between 280 and 450 
amino acids (HIV-1 IN: 288 amino acids, 32 kDa), and are characterized by three functional domains: 
(i) the N-terminal domain, containing an HHCC zinc-binding motif, (ii) the catalytic core domain 
(residues 50-212 of HIV-1), containing the critical magnesium-binding D-D-35-E motif that 
constitutes the active site, and (iii) the C-terminal domain. The three domains of IN appear to be 
involved in DNA binding and multimerization. Indeed, the full concerted integration seems to require 
an IN tetramer, i.e., one IN dimer at each viral end [10-14]. 
Although unintegrated viral DNA can be used as template for viral transcription [15-17], integration 
is required for productive viral replication. However, the efficiency of integration is quite low, and 
depends on restrictions occurring during the early steps of infection. By infecting human osteosarcoma 
(HOS) cells with VSV-G pseudotyped HIV particles, Thomas et al. measured that only 5% of HIV 
viruses successfully entered the cell and initiated reverse transcription [18]. Of these, 28% (i.e., 1.5% 
total) completed reverse transcription, translocated to the nucleus (with an efficiency ranging around 
2-3% according to data using IN-eGFP fusion proteins from Cereseto and collaborators [19,20]) and 
finally only ~13% of viruses that initiated reverse transcription achieved insertion in the host cell 
genome, which represented 0.41% of the virus input [18].  
The site of viral DNA insertion is critical for the virus, as it can influence the rate of viral 
transcription. Indeed, integration into transcriptionally active regions may favor viral gene expression, 
thus facilitating productive infectious progeny particles, while integration into transcriptionally 
repressed chromatin may disfavor viral gene expression, thus possibly facilitating viral latency  
[21-24]. 
The ability of retroviruses to integrate has also important consequences for the host as it can affect 
the expression of genes surrounding the proviral DNA. Indeed, viral DNA disruptive insertion into a 
gene may alter its expression (reduced gene expression), thereby potentially affecting cellular 
physiology. More importantly, the activity of inserted viral promoters or enhancers near cellular genes 
may also affect their physiological expression (increased gene expression), potentially leading to 
tumorigenesis when these genes are proto-oncogenes [25,26]. This process, known as insertional 
mutagenesis, raised justified critical issues regarding the safety of retroviral-based vectors used in gene 
therapy (for reviews, see [27-32]). However, not all retroviruses display the same genotoxic potential, 
as gammaretroviruses for example appeared to be more prone to insertional mutagenesis than 
lentiviruses [33-37]. This phenomenon can be partly explained by their preferred genomic site for 
proviral DNA insertion, i.e., into promoter regions for gammaretroviruses and along transcription units 
for lentiviruses. 
It is now clear that the chromosomal site of viral DNA integration is not random, but in contrast that 
retroviruses display specific preferences at distinct genomic positions. This review will summarize the 
current knowledge about retrovirus-specific favored integration sites, as well as the current models 
explaining these preferences. 
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Figure 1. Overview of the early steps of HIV-1 life cycle. (A) To enter a target cell, HIV-1 gp120 
binds to specific cellular receptors, i.e., CD4 and a chemokine coreceptor (CCR5 or CXCR4), 
triggering the gp41-mediated fusion between the viral and the cellular membrane, and releasing the 
viral core in the cytoplasm of the host cell. The viral single stranded, positive, RNA genome (black 
line, flanked by open black squares depicting R-U5 and U3-R in its 5’ and 3’ termini respectively) is 
reverse transcribed into a linear double stranded cDNA copy (red line, flanked by open red squares 
representing the LTR = U3-R-U5), which is a component of the preintegration complex (PIC), also 
containing the viral integrase (IN), as well as other viral and cellular proteins. The PIC is translocated 
to the nucleus and the viral cDNA is either integrated through the action of IN or remains unintegrated 
(linear, 1-LTR circles, 2-LTR circles). From this point on, the cellular machinery of the host is 
recruited to transcribe the viral genome in order to produce all the components required to generate 
newly infectious particles. (B) The integration process is divided into three major steps: the 3’ 
processing and the strand transfer reaction, both catalyzed by IN, and the repair of the integrated viral 
DNA by the DNA repair machinery of the host cell. The PIC-containing viral DNA (red line, with 5’ 
ends depicted by filled circles) is first processed by the IN-mediated removal of a dinucleotide (GT) at 
each 3’ end of the viral DNA, leaving a protruding (AC) dinucleotide at the 5’ ends. IN then catalyzes 
the stable insertion of the processed viral DNA into a target DNA (black line), by simultaneously and 
asymmetrically breaking the target DNA 5 bp apart (blue bonds) (4 to 6 bp depending on the 
retrovirus) and joining it to the 3’ recessed ends of the viral DNA, leaving an integration intermediate 
with unpaired bases at each viral-target DNA junction. The DNA repair machinery of the host cell fills 
in the five nucleotide gap at each side of the viral DNA and removes the two 5’ overhang nucleotides 
from the viral DNA, resulting in the duplication of 5 bp of the target DNA at both sides of the proviral 
DNA. (C and D) Schematic concepts of in vitro integration assays showing half-site integration (C) 
and concerted or full-site integration (D). 
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2. Integration targeting in vitro  
In vitro, IN is sufficient to carry out the first two steps of the integration reaction, i.e., 3’ processing 
and strand transfer reactions, resulting in the covalent attachment of the viral DNA on virtually any 
DNA target (random integration) (Figure 1B) [38]. To succeed, three principal components are 
minimally required: (i) purified viral integrase, (ii) a donor DNA mimicking a viral DNA terminal 
sequence to be recognized by IN, and (iii) an acceptor DNA in which the donor DNA will be inserted 
(for more details, see [7]). 
In the first in vitro assays, the donor DNA consisted in short oligonucleotide duplexes (21 bp 
minimum) containing the terminal LTR sequence (either U3 or U5), allowing to reproduce the 3’ 
processing efficiently, as well as the strand transfer reaction (albeit with lower efficiency). However, 
these were only half-site integration as only one donor DNA (e.g. one viral LTR) was inserted in the 
acceptor DNA (Figure 1C) [39], and not both in a concerted motion. This gave rise to the development 
of new assays, full-site or concerted integration assays, which use a longer donor DNA containing both 
terminal sequences (Figure 1D) [40,41]. 
 These studies showed that in vitro, HIV IN displayed only a weak preference for the primary DNA 
sequence [42-49], slightly favoring the palindromic TNNGT(A/T)ACNNA DNA sequence (bold 
nucleotides indicate the asymmetrical insertion points, resulting in the final 5 bp duplication flanking 
the proviral DNA, depicted in blue in Figure 1B). Furthermore, the addition of nucleosomes on the 
target DNA improved the in vitro efficiency of integration, and favored integration on distorted DNA 
and outwardly-facing major grooves sites of the nucleosomal DNA [44,46,47,50-53].  
In order to investigate whether simple tethering of IN to a specific DNA site could confer 
integration preferences in vitro, fusions of IN to specific DNA binding proteins were engineered [54]. 
The fusion of HIV IN to the DNA binding domain of  repressor (R) lead to increased integration 
targeting at sites surrounding the predetermined R DNA binding sites (operator sites) [54]. Fusion 
of IN with other DNA binding proteins such as LexA [55] or the polydactyl Zinc finger protein E2C 
[56] reached similar results. These studies provided proof-of-concept that integration site selection in 
vitro could be modified and redirected more preferentially to specific DNA sites. 
3. Integration targeting in vivo 
The availability of the human genome sequence and other vertebrate genomes made possible to 
interrogate where in the host cell genome retroviruses integrated, and more precisely what were the 
chromosomal features (according to current genomic annotations) that were favored for retroviral 
integration. To achieve this, host DNA regions flanking the proviral DNAs were amplified, sequenced, 
and finally aligned to the host genome sequence (method overview reviewed in [32,57,58]).  
Schroder et al., in 2002, revealed for the first time that HIV favored integration in transcription 
units and disfavored Alu repeats [59]. One year later, Wu et al. showed that murine leukemia virus 
(MLV) had distinct preferences, favoring integration at transcription start sites and CpG islands [60]. 
Since then, multiple genome-wide studies confirmed these preferences and revealed the integration site 
preferences for almost all retroviral genera, with the exception of epsilonretroviruses (Tables 1 and 2).  
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Table 1. Major genome-wide studies of retroviral integration distribution. 
Retroviridae genera Specimen a Host cell type b 
Approx. Nb. of sites 
investigated c 
       References 
     
lentiviruses HIV-1 human 59869 [23,36,59-76] 
  other 2421 [37,77-81] 
 HIV-2 human  202 [82] 
 SIV human 148 [83] 
  simian 501 [84] 
 EIAV human 1241 [69,81] 
  other 70 [81] 
 FIV human 226 [85] 
     
alpharetroviruses ASLV human 695 [62,86] 
  avian 658 [77] 
     
betaretroviruses MMTV human 298 [87] 
  murine 170 [87] 
     
gammaretroviruses MLV human 4005 [60,66,70,73,88] 
  murine 189 [37] 
  other 953 [78,79,84] 
 MSCV murine 259 [89] 
 PERV human 1962 [90,91] 
 XMRV human 472 [92] 
     
deltaretroviruses HTLV-I human 1235 [93-95] 
     
epsilonretroviruses Not investigated    
     
spumaviruses FV human 3457 [65,70] 
  other 263 [78] 
     
Endogenous retroviruses HERV-K human 1565 [88] 
 
a  HIV: human immunodeficiency virus; SIV: simian immunodeficiency virus; EIAV: equine 
infectious anemia virus; FIV: feline immunodeficiency virus; ASLV: avian sarcoma leukosis virus; 
MMTV: mouse mammary tumor virus; MLV: murine leukemia virus; MSCV: murine stem cell 
virus; PERV: porcine endogenous retrovirus; XMRV: xenotropic murine leukemia virus-related 
virus; HTLV: human T-cell lymphotropic virus; FV: foamy virus; HERV: human endogenous 
retrovirus. 
b  Host cell type includes human, simian, murine, canine and avian cells. Are indicated the human 
cells and the host cell type specific to each specimen. Other: non human and non species-specific 
host cell type.  
c  Number of integration sites analyzed in untreated/control cells according to the original publication. 
 
These studies demonstrated that in vivo the site of retroviral integration was not random, and that 
integration site preferences were retrovirus-specific (Table 2): lentiviruses favor integration in active 
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transcription units, with no preference along the transcript, nor for introns or exons; 
gammaretroviruses, spumaviruses and endogenous retroviruses (HERV class II) integrate 
preferentially around transcription start sites and CpG islands, features associated with host gene 
promoters; alpharetroviruses and deltaretroviruses displayed only weak preferences for integrating in 
transcription units and CpG islands; and finally betaretroviruses show no integration site preferences, 
displaying a random distribution of integration sites in the host genome. 
The integration site preferences are not host-specific as the same distribution of integration sites can 
be observed in different host vertebrate cells, including human, simian, murine, avian and canine cells 
(Table 1). Furthermore, integration targeting is independent of the route of viral entry, as HIV-based 
vectors using a natural CCR5-tropic HIV envelope or a VSV-G pseudotype envelope displayed the 
same integration site distribution [67]. 
Table 2. Chromosomal features associated with preferential retroviral integration sites. 
Retroviridae genera in Transcription Unitsa ± 2kb Transcription Start Sitesa ± 2 kb CpG Islandsa 
Lentiviruses +/++ 0 -/0 
Alpharetroviruses + 0 + 
Betaretroviruses 0 0 0 
Gammaretroviruses + ++ ++ 
Deltaretroviruses + + + 
Epsilonretroviruses NA NA NA 
Spumaviruses 0 ++ ++ 
HERV-class II + ++ ++ 
a  ratio between the proportion of the chromosomal feature over the random proportion in the human 
genome, according to RefSeq databases and with values from [69,87,88,90,94,95].  
 0: no statistical difference over random;  
 +/++: statistically favored feature over random with ++ for ratio >2 and + for a ratio <2;  
 -: statistically disfavored feature over random 
 NA : not available 
 
Three models, which are not mutually exclusive, have been proposed to date to explain integration 
site selection: (i) chromatin accessibility, (ii) cell cycle effects, and (iii) tethering mechanism. 
However, while the first two models can globally influence integration site targeting, only the last one 
- integration by a tethering mechanism - can provide a logical explanation to the observed differences 
of integration targeting preferences among retroviruses. 
3.1. The chromatin accessibility model 
According to this model, the structure of the chromatin, either relaxed or condensed, may influence 
the accessibility of target DNA sequences to preintegration complexes, thereby affecting integration. 
In vivo, retroviral integration displayed a weak preference for the primary DNA sequence, similar to 
the one observed in vitro [60,69,70,72,90,94,96-99]. Furthermore, HIV integration in vivo also favors 
major grooves facing outwards from the nucleosome core, as predicted by nucleosome positioning 
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[72,100]. These data indicated that local chromatin structure, such as A/T-rich distorted DNA and 
outwardly-facing major grooves of the nucleosomal DNA, may facilitate integration, however this 
cannot fully explain the observed differences in retroviral integration site distribution.  
The retroviral differences in favored integration target site selection observed in vivo argued against 
chromatin accessibility being the principal determinant explaining integration targeting (Table 2). 
Indeed, if the accessibility of chromatin was the key player, all retroviruses would display the same 
integration site distribution pattern, favoring reachable chromatin. 
Additional evidence against this model playing a major role in integration targeting came from the 
correlation analysis of mapped HIV and MLV integration sites with mapped DNase I hypersensitive 
sites. DNase I cleavage sites are used as a surrogate marker for accessible chromatin, and are enriched 
in the 5’ ends of transcription units and CpG islands [66,101]. This study revealed that MLV 
integrated preferentially in 2-kb intervals surrounding DNase I hypersensitive sites, compatible with 
favored MLV integration sites in promoter regions. In contrast, HIV integration did not display such a 
preference, consistent with favored integration in transcription units and not promoter regions. 
Therefore, although chromatin accessibility may influence MLV integration site preferences, it does 
not seem to affect significantly HIV integration site distribution. 
In conclusion, even though chromatin structure can facilitate integration, chromatin accessibility 
cannot solely explain the differences observed in integration site preferences between HIV and MLV.  
3.2. The cell cycle model 
This model implies that the phase of the cell cycle may influence integration site selection. Indeed, 
lentiviruses can infect and successfully integrate regardless of the cell cycle stage (dividing or non-
dividing) thanks to the active nuclear import of the PIC, while gammaretroviruses can integrate only 
into dividing cells as they require the disruption of the nuclear membrane occurring during mitosis to 
contact the host genome. Thus, it is possible that this difference in cell cycling status during viral 
infection might affect integration site distribution.  
To test this hypothesis, HIV integration site distribution was compared between dividing IMR-90 
primary lung fibroblasts and non-dividing G1-arrested IMR-90 cells [64]. HIV integration in active 
transcription units was favored in both dividing and non-dividing cells, with even stronger preferences 
in non-dividing cells. Similarly, analysis of HIV integration site distribution in non-dividing 
differentiated human macrophages also revealed a marked preference for transcription units [67,74]. 
Comparison between quiescent CD4+ T cells and activated CD4+ T cells revealed a similar integration 
site distribution with favored integration in transcription units and other chromosomal features (gene 
density, GC-rich regions, DNase I sites), although to a lower extent for resting cells [75,76].  
All together, these data argued against a major positive influence of cycling cells in guiding HIV 
integration in transcription units and cannot explain the integration site selection differences between 
HIV and MLV.  
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3.3. The tethering protein model  
This model implicates that a cellular protein, specific for each retroviral genera, would act as a 
tethering factor, binding both to specific chromatin sites and to the retroviral preintegration complex.  
In principle, any PIC component could serve as the docking point between the PIC and the 
integration site, thereby dictating the integration target site preferences. PIC candidates include both 
viral and cellular proteins. 
3.3.1. IN and Gag as major viral determinants in integration targeting 
To investigate the role of viral PIC components in integration site distribution, Lewinski et al. 
constructed chimeras between HIV and MLV encompassing Gag and IN regions [66]. The transfer of 
MLV Gag in HIV viruses did not affect the HIV integration site preferences of HIV, suggesting that 
HIV Gag was not involved in directing HIV integration site selection. The transfer of MLV IN into 
HIV viruses caused the hybrid to favor integration in transcription start sites and CpG islands, close to 
MLV phenotype. Addition of MLV Gag and MLV IN in HIV chimeric viruses increased the similarity 
of target site selection to that of MLV, suggesting that both MLV Gag and IN played a role in 
determining MLV integration site preferences. To summarize these data indicated that IN is the major 
viral determinant in shaping specific integration site preferences for HIV and MLV, with an additional, 
although minor, role of MLV Gag in MLV integration targeting. Recently, Felice et al. used a 
bioinformatic approach to show that in contrast to HIV, MLV integrated preferentially in regions 
enriched for transcription factor binding sites (as described in the JASPAR database) [73]. Using 
chimeric constructs for IN and the LTR U3 region between HIV and MLV, they showed that MLV IN 
was mostly responsible for this targeting, while the MLV U3 region could play a minor role [73]. 
Recently, Tobaly-Tapiero et al. identified a chromatin-binding site in the C-terminus of Gag, 
essential for PIC binding to host chromosomes, by interacting with H2A/H2B core histones, 
suggesting that Gag may be a major viral determinant dictating foamy virus (FV) integration site 
selection, through H2A/H2B tethering [102]. 
3.3.2. LEDGF/p75 as the major cellular determinant in lentiviral integration targeting 
Any cellular protein able to bind both chromatin and HIV IN (the major determinant involved in 
HIV integration targeting) may represent a candidate tethering factor. Numerous cellular proteins have 
been proposed, such as IN-interactor 1 (Ini-1), barrier to autointegration factor (BAF), high mobility 
group A1 (HMGA1), heat shock protein 60 (Hsp60) and lens epithelium-derived growth factor 
(PSIP1/LEDGF/p75) [2,103-108].  
To date, only LEDGF/p75 proved to be a bona fide tethering protein, recruiting lentiviral PICs to 
transcription units, thereby promoting integration efficiency as well as dictating lentiviral integration 
site selection [32,109-111].  
LEDGF/p75 is a 530 amino-acid bimodal protein containing a large N-terminal domain (comprising 
a PWWP motif, a nuclear localization signal, a dual AT-hook motif and charged regions) responsible 
for chromatin binding, and a C-terminal domain involved in protein-protein interaction and containing 
the IN-binding domain [110-112]. LEDGF/p75 is a ubiquitously expressed cellular protein and its 
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cellular role has yet to be fully characterized. Proposed roles for LEDGF/p75 include transcriptional 
activity function [113], autoantigen in atopic dermatitis and inflammatory conditions [114], and cell 
survival [115]. Despite an increased perinatal mortality, mice knocked-out for the LEDGF/p75-
encoding psip1 gene survived to adulthood with a range of developmental and neurobehavioral 
abnormalities, suggesting that LEDGF/p75 is not essential for organism survival [116]. 
Studies using RNAi to knock-down LEDGF/p75 expression or knock-out murine cells 
demonstrated that HIV and lentiviruses in general required LEDGF/p75 to efficiently integrate into the 
host genome [80,117,118]. Indeed, LEDGF/p75-depleted cells revealed a 10-40x decrease in infection 
efficiency as compared to LEDGF/p75 expressing cells. Furthermore, the analysis of lentiviral (HIV 
and EIAV) integration site distribution in cells depleted for LEDGF/p75 revealed an altered integration 
site selection profile, with a decreased preference for transcription units, as well as an increased 
targeting in transcription start sites and CpG islands, a pattern resembling MLV integration site 
preferences [63,80,81]. However, LEDGF/p75 did not affect the weak consensus primary DNA 
sequence favored by lentivirus integration, further suggesting that chromatin structure may facilitate 
integration more than dictating integration target sites. These data also suggest that, in absence of 
LEDGF/p75, other tethering proteins might recruit lentiviral PICs, and promote their integration in 
new specific chromosomal locations. 
Consistent with LEDGF/p75 recruiting lentiviral PICs to specific favored integrations, the 
distribution profile of LEDGF/p75 on host chromosome should parallel HIV integration site 
distribution profile. In order to investigate this, De Rijck et al. used the Dam methylase fused to the N-
terminal domain of LEDGF/p75, a technology known as DamID [119]. Sites bound by LEDGF/p75 
would induce methylation of proximal adenosine residues in the GATC recognition motif, which can 
subsequently be identified. DamID analysis of LEDGF/p75 proximal genomic site distribution 
revealed that LEDGF/p75-binding sites were enriched in genes and poorly present in promoters and 
intergenic regions, a distribution pattern reminiscent of HIV integration preferences [119]. Preliminary 
analysis of DNA sequences bound to LEDGF/p75 or LEDGF/p75-containing complex using a 
chromatin immunoprecipitation-based approach followed by high-throughput sequencing (ChIP-Seq) 
also revealed a distribution of LEDGF/p75-captured DNA sequences throughout the transcription 
units, paralleling HIV integration site distribution [120]. Moreover, so far, these studies did not 
highlight any DNA binding motif specific for LEDGF/p75 [120].  
An additional argument for LEDGF/p75 being the major lentiviral tethering protein used the IN-
binding domain containing C-terminal portion of LEDGF/p75 fused to an alternate N-terminal domain 
displaying distinct DNA or chromatin binding preferences [121-124]. This was exemplified first in 
vitro using R-LEDGF/p75 fusion proteins [121] and was recently confirmed in vivo as well  
[122-124]. Indeed, using LANA31 or histone 1-LEDGF/p75 chimeric proteins, Meehan et al. showed 
that they could rescue infectivity in LEDGF/p75 depleted cells [122]. Furthermore, the fusion of 
LEDGF/p75 to heterochromatin protein 1 (CBX5) [123] or heterochromatin protein 1 (CBX1) [124] 
altered HIV integration site selection, redirecting integration preferences from active transcription 
units to heterochromatin regions, thereby giving final proof for the tethering role of LEDGF/p75. 
Interestingly, these studies demonstrated that integration targeting site preferences may be modified in 
vivo, being of potential interest for improving safety of retroviral-based gene therapy vectors.  
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Up to now, LEDGF/p75 is the only tethering protein described for lentiviruses. However, alternate 
cellular proteins are likely to play a role in lentiviral PIC tethering as well. Foamy virus integration 
involved Gag tethering to H2A/H2B core histones [102]. Tethering proteins involved in integration of 
other retroviral genera are yet to be described. 
To date, 13 proteins interacting with MLV IN have been identified by yeast two-hybrid and 
represent potential tethering protein candidates dictating MLV integration site selection preferences 
for promoter regions, as they are chromatin-binding proteins or transcription factors [125]. These 
candidates include transcription factors (TFIIE-, B-ATF, Znfp15, Znfp38, Ankrd49, AF9), chromatin 
remodeling factors (brd2, Enx-1) and factors involved in DNA repair (Ku70, fen1). These putative 
candidates are consistent with an enrichment of transcription factor binding sites surrounding MLV 
integration sites [73]. Interestingly, some of the MLV IN interacting proteins (AF9, brd2, Znfp38, 
Ku70 and fen1) also interact with HIV IN in yeast two-hybrid, suggesting that they might play a role 
in HIV integration targeting in promoters in the absence of LEDGF/p75 [125]. 
3.3.3. Epigenetic modifications and integration targeting 
The Encyclopedia of DNA Elements (ENCODE) contains ~1% of the genome that is extensively 
annotated, allowing comparisons of epigenetic marks with retroviral integration site preferences 
[126,127]. Consistent with previous findings on favored insertion in active transcription units, 
lentiviral integration sites associated significantly with the epigenetic marks H3K4me, H3K36me, 
H3K9/K14Ac and H4Ac, histone modifications usually associated with transcriptionally active 
chromatin. In contrast, lentiviral integration sites were disfavored in regions containing DNA CpG 
methylation as well as H3K9me2/3, H3K27me2/3 and H3K79me3, epigenetic marks usually 
associated with repressed chromatin [72,76]. A similar association pattern was observed for 
alpharetroviruses, gammaretroviruses and HERV-K [88]. 
Recently, LEDGF/p75 was identified as a cellular partner of the menin/MLL complex [128]. The 
menin/MLL histone methyltransferase complex promotes specific trimethylation of histone 3 on lysine 
4 (H3K4me3), an epigenetic mark associated with active transcription. This histone modification is 
also associated with HIV integration sites, coherent with a global picture in which, LEDGF/p75, 
epigenetic marks associated with transcriptional activity and HIV integration sites converge to similar 
genomic locations. 
4. Conclusions  
LEDGF/p75 was initially identified in a complex co-immunoprecipating with positive cofactor 4 
(PC4), a general coactivator of transcription [113,129]. PC4 has been involved in many transcription 
steps: (i) PC4, by interacting with upstream activators and the general transcriptional machinery, can 
enhance the efficiency of pre-initiation complex assembly, thereby promoting transcription initiation, 
in cooperation with TBP-associated factors (TAFs) [130]; (ii) PC4 improves transcription activation 
by stimulating promoter escape [131]; (iii) Sub1, the yeast PC4 homolog, facilitates transcription 
elongation and may also prevent premature transcription termination [132]. Thus, being associated to a 
PC4-containing complex, itself associated with the transcription machinery, it is reasonable to 
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hypothesize that LEDGF/p75 might be associated with the RNA polymerase II complex during 
elongation. 
Therefore, based on the current knowledge about HIV integration site selection, i.e., preferentially 
integrating into active transcription units, it is tempting to speculate a dynamic, more than a static, 
tethering model, in which LEDGF/p75 would be associated with PC4 and the RNA polymerase II 
elongation complex (Figure 2). In this model, LEDGF/p75 would recruit HIV preintegration complex 
while transcribing genes or at pausing sites, thereby explaining integration sites all along the 
transcription units. 
Figure 2. Dynamic model depicting the mechanism of LEDGF/p75-mediated HIV 
integration. LEDGF/p75 (green oval) associates with PC4 (red protein) and the RNA 
polymerase II machinery (yellow ovals) at promoter regions, but steric hindrance may 
prevent successful recruitment of preintegration complexes (gray oval with viral DNA in 
red). In this proposed model, LEDGF/p75 remains associated with the RNA pol II 
transcription elongation complex, potentially interacting with PC4 and menin/MLL 
complex. While this complex displaces nucleosomes (not depicted) and unwinds DNA to 
allow RNA polymerization, LEDGF/p75 may recruit HIV PIC and promote integration. 
This model is consistent with LEDGF/p75-captured DNA sequences and HIV integration 
sites being present throughout the transcription unit, without specific DNA binding 
consensus motif. 
 
 
Consistent with these results are (i) integration in active transcription units, with no preference 
along the transcription unit, neither for exons, nor for introns, (ii) LEDGF/p75 initially characterized 
as a transcriptional coactivator, associated with the transcription machinery (via PC4-containing 
complex), (iii) LEDGF/p75 interaction with the menin/MLL histone methyltransferase, involved in 
H3K4me3 histone modification, a mark associated with active transcription, and (iv) no sequence 
consensus for LEDGF/p75-binding DNA sites, suggesting that the N-terminal domain of LEDGF/p75 
may serve as a hook to anchor the protein to the chromatin but that the location specificity is given by 
an additional chromosome-bound protein, yet to be identified.  
Further studies on LEDGF/p75 should help refining the detailed mechanism of LEDGF/p75-
mediated HIV integration. 
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